Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
EHA 2024 – Syndax sets up another menin inhibitor battle
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
